TAK-779, a nonpeptide CC chemokine receptor antagonist, protects the brain against focal cerebral ischemia in mice

J Cereb Blood Flow Metab. 2002 Jul;22(7):780-4. doi: 10.1097/00004647-200207000-00003.

Abstract

The effect of a nonpeptide CC chemokine receptor antagonist, TAK-779, on ischemic brain injury resulting from 1-hour middle cerebral artery occlusion followed by 48-hour reperfusion was examined in ddY mice. On intracerebroventricular injection of vehicle or TAK-779, infarct volume in the vehicle-treated group was 44.2 +/- 13.2% of the contralateral hemispheric volume, and TAK-779 (25 and 250 ng/mouse) dose-dependently reduced the infarct volume to 35.0 +/- 12.2% and 31.1 +/- 12.9%, respectively. On intravenous injection, infarct volume in the vehicle-treated group was 32.0 +/- 16.1%, and TAK-779 (5 microg per 20 g body weight) significantly reduced this to 22.0 +/- 10.5%. The results showed for the first time that a nonpeptide chemokine receptor antagonist is protective against ischemic brain injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / administration & dosage
  • Amides / therapeutic use*
  • Animals
  • Brain / pathology
  • CCR5 Receptor Antagonists*
  • Chemokine CCL4
  • Immunohistochemistry
  • Injections, Intravenous
  • Injections, Intraventricular
  • Ischemic Attack, Transient / etiology
  • Ischemic Attack, Transient / pathology
  • Ischemic Attack, Transient / prevention & control*
  • Leukocytes / pathology
  • Macrophage Inflammatory Proteins / analysis
  • Male
  • Mice
  • Middle Cerebral Artery / surgery
  • Peroxidase / analysis
  • Quaternary Ammonium Compounds / administration & dosage
  • Quaternary Ammonium Compounds / therapeutic use*

Substances

  • Amides
  • CCR5 Receptor Antagonists
  • Chemokine CCL4
  • Macrophage Inflammatory Proteins
  • Quaternary Ammonium Compounds
  • TAK 779
  • Peroxidase